The classification of fibromyalgia syndrome

被引:53
作者
Mueller, W.
Schneider, E. M.
Stratz, T.
机构
[1] Rheumatol Forsch Abt, D-79713 Bad Sackingen, Germany
[2] Univ Ulm Klinikum, Anasthesiol Klin, Sekt Expt Anasthesiol, D-89075 Ulm, Germany
[3] Rheumaklin Bad Sackingen, D-79713 Bad Sackingen, Germany
关键词
fibromyalgia; subgroups; tropisetron; 5-HT3-receptor; treatment;
D O I
10.1007/s00296-007-0403-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As has been shown by a number of working groups, primary fibromyalgia syndrome does not represent a single clinical entity. It is possible to distinguish between a subgroup with high pain sensitivity and no associated psychiatric condition, a second and a third subgroup characterized by depression associated with fibromyalgia syndrome, and a fourth group with somatoform pain disorder of the fibromyalgia type. Mild inflammatory processes must be considered as the cause in the first group, while depression is combined with fibromyalgia in the second and the third group. In the fourth group, serious previous or still existing psychological problems or also insufficient coping with illness symptoms must be regarded as the reason for pain chronification. Group 1 benefits from a blocking of the 5-HT3 receptors by means of tropisetron, for example. This does not only affect pain chronification but also the inflammatory process itself. Group 2 and 3 needs antidepressant treatment, whereas the focus should be on psychotherapy in group 4. Groups 1, 2 and 3 will also profit from multimodal physical treatment programs, to a certain extent this applies to group 4 as well. So-called mixed types require a combination of therapeutic measures.
引用
收藏
页码:1005 / 1010
页数:6
相关论文
共 34 条
[1]   Citalopram in patients with fibromyalgia - a randomized, double blind, placebo-controlled study [J].
Anderberg, UM ;
Marteinsdottir, I ;
von Knorring, L .
EUROPEAN JOURNAL OF PAIN-LONDON, 2000, 4 (01) :27-35
[2]   A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder [J].
Arnold, LM ;
Rosen, A ;
Pritchett, YL ;
D'Souza, DN ;
Goldstein, DJ ;
Iyengar, S ;
Wernicke, JF .
PAIN, 2005, 119 (1-3) :5-15
[3]   Fibromyalgia: Present to future [J].
Bennett R. .
Current Pain and Headache Reports, 2004, 8 (5) :379-384
[4]  
Burckhardt C S, 1994, Arthritis Care Res, V7, P35
[5]  
EGLE UT, 2005, MMW-FORTSCH MEDIZIN, V147, P6
[6]  
Färber L, 2000, SCAND J RHEUMATOL, V29, P49
[7]   Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes [J].
Fiebich, BL ;
Akundi, RS ;
Lieb, K ;
Candelario-Jalil, E ;
Gmeiner, D ;
Haus, U ;
Müller, W ;
Stratz, T ;
Muñoz, E .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2004, 33 :28-32
[8]  
Gendreau RM, 2005, J RHEUMATOL, V32, P1975
[9]  
GIESECKE T, 2004, ARTHRITIS RHEUM, V50, P2716
[10]  
Häuser W, 2006, SCHMERZ, V20, P128, DOI 10.1007/s00482-005-0391-1